"BEONE MEDICINES LTD."Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)
Filed with SSE · · 4 pages · Chinese
Earlier from Beone Medicines Ltd. Class A
- Announcement on the Handling of Relevant Tax Matters
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
- Report for Q1 2026